Treatment options for unresectable pNETs or advanced metastatic disease may include biotherapies such as SSAs, interferon alpha, mechanistic target of rapamycin (mTOR) inhibitors, receptor tyrosine kinase (RTK) inhibitors, including platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR) inhibitors, and vascular endothelial growth factor A (VEGFA) antibodies. Here, KDR is linked to metastatic neoplasm.